Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.
about
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaEfficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Molecular therapy for acute myeloid leukaemia.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxideAdvances in treating acute myeloid leukemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisConnect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaOutcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia.The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemiaAcute myeloid leukemia and myelodysplastic syndromes in older adults.Targeted therapy of acute myeloid leukemia.Elderly acute myeloid leukemia: assessing risk.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.CpG island methylator phenotype and its relationship with prognosis in adult acute leukemia patients.Expert insights into the contemporary management of older adults with acute myeloid leukemia.The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Toona sinensis Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo.Improved outcome for AML patients over the years 2000-2014.Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.CDK9 inhibitors in acute myeloid leukemia.Initial therapy for acute myeloid leukemia in older patients: principles of care.Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.Incidence and survival of hematological cancers among adults ages ≥75 years.Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.
P2860
Q27336142-1304ACEE-F8DF-4108-91D1-11D4E2DA0A04Q28084813-5C1DB2D1-E534-46F5-B752-8C028317CAE6Q33417145-FF584D70-11B1-4303-9E45-8CA8516697DEQ33707331-6999A25F-9F09-480D-BC76-F19925497457Q33840247-904FF1A9-BC9D-4ADE-BB1B-DCA048136352Q33925672-557409A3-0A6F-4545-A2A0-3654921D1461Q34121354-E45C28C2-EFDB-41D9-99DC-92924C871605Q34312351-6700AFF7-6F43-4E99-8AB0-F1220E3CB0BAQ34428556-AE0EB7BB-DA9D-44B9-91C2-14346ADAC454Q36107268-EACA492F-2618-49D3-A68B-A9AD54D89EF1Q36279306-619E546B-0C0F-4EB3-85D5-1B1C2F917A20Q36723291-9A464239-69AF-4D11-9195-CB20FF8097F3Q36742031-CF45C02F-1BB6-4294-B6CC-44552E4B6A5BQ36866323-7BE0CF69-D100-434C-B933-F0000971A11BQ38234863-2BAB457B-56A4-45A1-989F-F13534417B8AQ38333251-C570192B-C4AE-4400-855D-CBE3EB27402CQ38458166-ACD49F88-6C26-4693-8C1D-B0BC84319D1AQ38797003-680DBD6E-3E9B-4B52-A3B1-021186CCA095Q38918850-1B26617D-EF97-4C30-B50E-89FDAAF0D015Q38967020-AD59AD66-0838-4715-A453-3A254AE46F58Q39311595-178694F3-751E-4DDA-8679-C3DE7945ADD6Q39342733-03AD7149-0C77-418E-9FDB-BFAC5746F491Q40376093-7D60F7AD-E1B2-4935-A76E-DCE5435518C6Q40548451-D15F27BB-2114-4707-A0CF-FD05F3591445Q40727176-20EB66F9-FD1F-49C7-9CC0-724810DBFE70Q43649407-84B08491-C0E1-45E9-A8E4-02907EDA14ADQ44898238-ADEE3C87-CE46-49FF-896A-A3C91F0124BDQ47450476-342577AC-CE16-465C-A543-EFE253D36526Q48154329-584EDE3F-A134-448A-8BBD-B07B38FC8AF3Q49221676-E8BDEE28-AF78-483D-9E2F-CE1110857E3BQ49566124-A2CDEC23-AF18-4D71-ACC6-F7125C3C60F6Q50028184-45DF1381-034F-4281-A3C8-B7F209BF6A0DQ50318294-DC68921B-C3C7-4FA4-B6F9-FE4638D7C747Q52767299-67EE3E03-DA1F-4CF8-9C09-F28E982C26B3Q52867206-34603228-AD00-4E15-AA24-D36B5E6EB1EAQ54212475-67CBE0BE-F34A-4C03-AB34-F4788CEAA059Q54342150-4AC56156-ED6B-450D-9625-7BE494287A31Q55355645-BF2883CB-A4D7-4E45-8CB1-156941B1E12E
P2860
Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Outcome of older patients with ...... s of SEER data over 3 decades.
@ast
Outcome of older patients with ...... s of SEER data over 3 decades.
@en
type
label
Outcome of older patients with ...... s of SEER data over 3 decades.
@ast
Outcome of older patients with ...... s of SEER data over 3 decades.
@en
prefLabel
Outcome of older patients with ...... s of SEER data over 3 decades.
@ast
Outcome of older patients with ...... s of SEER data over 3 decades.
@en
P2093
P2860
P356
P1433
P1476
Outcome of older patients with ...... s of SEER data over 3 decades.
@en
P2093
Ahmedin Jemal
Jerome W Yates
Maria R Baer
Mya S Thein
William B Ershler
P2860
P304
P356
10.1002/CNCR.28129
P407
P577
2013-04-30T00:00:00Z